Add us as a Preferred Source on Google

Scaling up n-of-1 trials; and more

Here is a roundup of autism-related news and research spotted around the web for the week of 16 November.

By Jill Adams
17 November 2026 | 2 min read

n-of-many: A new study details a strategy to scale up genetic therapies that have, to date, only been tested in n-of-1 trials. Antisense oligonucleotides were custom-made for two people with SCN2A-complex neurodevelopmental disorder, a severe childhood-onset condition that can result in autism and epileptic encephalopathy. Gene-specific haplotyping enabled researchers to identify additional people with compatible diplotypes. The investigators envision prequalifying a small set of antisense oligonucleotides that target the most common SCN2A causal variants. The Transmitter has previously covered the promise and concerns over n-of-1 trials. 

Autism research spotted this week:

Research image of human thalamus.
Complete coverage: An analysis of the developing human brain finds expression of most autism-linked genes in the thalamus.
  • “Anterior cingulate input tunes striatal dynamics for context-dependent social preference in a mouse model of autism” Nature Communications
  • “Druggable CSNK2A1-MeCP2 regulatory axis links Okur-Chung neurodevelopmental syndrome with MECP2-related disorders” bioRxiv
    See also: “Finding the Rett syndrome gene and ways to fix it”
  • “Infant sensory over-responsivity: Relations to early life adversity, emerging behavioral problems, and sensory functional connectivity” bioRxiv

Sign up for the weekly Spectrum newsletter.

Stay current with the latest advancements in autism research.